Contact
QR code for the current URL

Press release Box-ID: 1080711

SIRION BIOTECH GmbH Am Klopferspitz 19 82152 Martinsried, Germany https://www.sirion-biotech.de
Company logo of SIRION BIOTECH GmbH
SIRION BIOTECH GmbH

SIRION Biotech Granted CIR accreditation by French Ministry of Higher Education, Research and Innovation

(PresseBox) (Martinsried, )
The French Ministry of Higher Education, Research and Innovation have granted SIRION Biotech a 3-year CIR (Crédit Impôt Recherche) accreditation lasting until end of 2023.

As a result, SIRION Biotech GmbH is now on a list of experts accessible on the Ministry website, and companies based in France that work with us can deduct part of the research funds spent at SIRION Biotech from their taxes. This accreditation is the result of SIRION’s drive to improve support for clients in France and Worldwide, enabling them to go one step closer to developing cutting edge therapies with efficient viral vector technologies.

“It is a great achievement for us in France, a country we believe to be one of the most important in the Gene Therapy and Cell Therapy markets. With this accreditation we reinforce our support to French companies and open new paths towards more R&D collaborations.”, said CEO of SIRION Biotech, Dr. Christian Thirion.

Dr. Francois Vromman, Senior Director, Head of Business Operations, Southern and Western Europe, and Head of SIRION Biotech’s Paris office, added: “We wish to thank the @Businove team with @Romain Bouverot and @Angelique Richard for helping us through the process”

Website Promotion

Website Promotion

SIRION BIOTECH GmbH

SIRION Biotech was founded in 2005 to lead the next generation of viral vector technologies for gene and cell therapy as well as vaccine development. Now SIRION offers one of the world’s most comprehensive viral vector technology platforms based on lenti-, adeno-, and adeno-associated viruses to expedite gene therapy research and advance drug development. SIRION is becoming a partner of choice in this growing sector. LentiBOOST® has been used in a number of clinical trials from early stage clinical Phase 1/2 through late stage clinical Phase 3 trials and demonstrated clinical success in improving transduction of the therapeutic vector.

The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.
Important note:

Systematic data storage as well as the use of even parts of this database are only permitted with the written consent of unn | UNITED NEWS NETWORK GmbH.

unn | UNITED NEWS NETWORK GmbH 2002–2022, All rights reserved

The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.